PRCT (40) IRMD (59) SGP (43) DRTS (39) ⌘ Pro Terminal →

Artivion Inc. (AORT) — RQD Stock Rating Cockpit

$23.44 +2.27% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.49

Artivion Inc. (AORT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.14B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AORT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Artivion Inc. (NYSE: AORT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $23.44 (+2.27% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, AORT ranks #497 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AORT compare to PRCT and IRMD in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D- (41/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B) and IRMD (iRadimed Corporation) posts a C- grade (59/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AORT?

▼

Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $23.49 (+0.22%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AORT)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY AORT SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 2.46 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (22% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 53.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 7.6% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$21.79+2.2% Next Q

Q2 (-2Q)

Grade E$22.28+3.1% Next Q

Q3 (-1Q)

Grade E$22.98+2% Next Q

Current

Grade D-$23.44-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AORT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AORT currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.77) and Max Pain ($24.61) forces dealer call-delta covering toward $50.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.630 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.46>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

9 / 99-Pt Accounting

52-WEEK LASER RANGE15% OF RANGE

L: $19$23.44H: $48

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on AORT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

4.5% ROIC with 64.4% gross margin and 0.07% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 2.46 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

14/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like AORT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Priced at 117x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AORT)

✓Walkthrough of AORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.03%▲ RESISTANCE BREAKOUT

2026-11-02O $22.92H $23.44L $22.92C $23.44VOL 418.2K

RES: $23.32SUP: $19.53SMA50: $23.77SMA200: $29.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AORT Butterfly Map → + Track AORT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AORT)

Health Care Rank #497 of 1016 ⚔️ PRCT vs AORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AORT vs. PRCT, IRMD, SGP, DRTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artivion Inc. (AORT) ranks #497 by composite RQD confidence (41/100, grade D-) and #344 by equity capitalization ($1.14B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with AORT at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AORT ACTIVE Artivion Inc.	D-	41/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	Benchmark Subject
PRCT PROCEPT BioRobotics Corporation	D-	40/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-aort →
IRMD iRadimed Corporation	C-	59/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-aort →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-aort →
DRTS Alpha Tau Medical Ltd.	D-	39/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-aort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000784199

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artivion Inc. (AORT) reported GAAP revenue of $441.3M (+13.6% vs. FY2024 revenue of $388.5M , and +24.7% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $39.9M, and free cash flow of $839.0K (-92.4% YoY). On the balance sheet, AORT closed FY2025 with $884.8M in total assets against $215.1M in total debt (Altman Z-Score: 2.46, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$441.3M	$9.8M	$39.9M	$839.0K	$884.8M	$215.1M
FY2024 (FY)	2024-12-31	$388.5M	-$13.4M	$22.2M	$11.0M	$789.1M	$314.2M
FY2023 (FY)	2023-12-31	$354.0M	-$30.7M	$18.8M	$18.8M	—	—

3. AORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AORT compare to PRCT and IRMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AORT?

Where is AORT trading relative to its 50-day, 200-day, and 52-week technical levels?

AORT last traded at $23.44 (+2.27% on volume of 418,218 shares), positioning the stock -1.39% below its 50-day simple moving average ($23.77) and -19.97% below its 200-day simple moving average ($29.29). Across its 52-week range of $19.16 to $48.25, AORT sits at the 14.7% percentile with a 14-day RSI of 53.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($21.28 to $25.60).

AORT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AORT stock right now?

Artivion Inc. (AORT) currently earns a Roarable Rating of D- (Sell — SELL) with 41/100 RQD Confidence. Stretched risk/reward at 117x P/E (5% return on capital) under elevated 10-year interest-rate pressure.

What is AORT's 12-month price target and RQD AI Jury consensus?

AORT's 12-month base price target is $21.65 (range $16.89 to $50.66), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AORT RQD Cockpit AORT 12M Forecast AORT Earnings & Move AORT Dividends & DRIP AORT Insiders & 13F AORT Whale Options AORT Profit Sankey AORT News & Why